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Targeted alpha therapy (TAT) using 225Ac-PSMA li-
gands is a promising therapy option for advanced met-
astatic castration-resistant prostate cancer (mCRPC) [1].
The 225Ac decay chain shows a noticeable gamma emis-
sion (440 keV, 25.9%; 218 keV, 11.4%). However, rec-
ommended low therapeutic activities (4–8 MBq) limit
the clinical applicability of SPECT [2], although initial
attempts for 225Ac imaging exist [3, 4]. Particularly
quantitative SPECT is a vital tool to assess dosimetry
and therapy response. While the 218-keV-peak is char-
acterized by a lower branching ratio and a higher scatter
fraction, SPECT imaging of high-energy gammas such
as 440 keV causes a complex detector point spread
function (PSF) [5].
In this study, we would like to demonstrate the gen-
eral feasibility of image-based dosimetry for 225Ac ra-
dionuclide therapy using quantitative 225Ac SPECT. For
a mCRPC patient (65 years), imaging of the abdomen
was performed 24 h p. i. of 8.1 MBq 225Ac-PSMA-I&T
on a Siemens Symbia Intevo T16 SPECT/CT (440 keV
(width, 20%), lower adjacent window (width, 10%),
HEGP collimator, 16 projections/head, 128 × 128 pixel,
210 s/projection). Reconstruction was carried out via a
MAP algorithm (30i1s) [6], including CT-based attenu-
ation and dual-energy-window scatter correction and a
simulated distance-dependent 2D PSF model (SIMIND).
Final absorbed dose assessment was performed by com-
bining the single 225Ac image with the effective half-life
information determined from a previous 177Lu-PSMA-
I&T imaging sequence [7]. This resulted in an absorbed
dose of 0.18 and 0.17 SvRBE = 5/MBq for the left and
right kidney, respectively, compared with 0.27 and
0.24 Gy/GBq for the preceding 177Lu cycle (6.2 GBq).
A comparison with the pre-therapy 18F-PSMA-I&T
PET/CT demonstrates that 225Ac SPECT imaging for
this patient was able to locate a small lesion in the right
hip. The 225Ac-absorbed dose was determined as 0.26
SvRBE = 5/MBq, compared with 0.35 Gy/GBq for
177Lu-
PSMA-I&T.
Our analysis demonstrates the feasibility of dosimetry for
225Ac-PSMA-I&T, which provides further insights into
theranostic approaches using TAT in mCRPC patients.
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